RNTX
NASDAQ
$0.84
Rein Therapeutics Inc (RNTX)
Rein Therapeutics Inc (RNTX) is a forward-thinking biopharmaceutical company dedicated to developing innovative therapies for neurodegenerative disorders through its proprietary technology platform that merges advanced neuroscience with drug development. With a robust pipeline aimed at addressing critical unmet medical needs, the company is positioned at the forefront of a rapidly evolving therapeutic landscape. Led by an experienced management team with a proven track record in the industry, Rein Therapeutics offers institutional investors a compelling opportunity to engage with transformative healthcare solutions that have the potential to drive significant patient impact and market growth.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $8 (+847.87%)
Market Cap
$52M
Free Cash Flow Yield
-37.38%
Beta (5Y)
0.87
Price Chart
Valuation
Market Cap$52M
P/B28.17
Profitability
EBITDA-$51M
EPS-$1.93
Financial Health
Free Cash Flow Yield-37.38%
Growth & Risk
EPS 5Y CAGR-37.84%
FCF 5Y CAGR-1.12%
Beta (5Y)0.87
Sharpe Ratio-0.13